Editorial Policies

Focus and Scope

The main mission of the journal «ScienceRise: Pharmaceutical Science» – dissemination of the results of scientific research aimed at ensuring the quality of pharmaceutical assistance to the population through targeted search and modern pharmaceutical development of innovative medicines, the creation of modern quality management systems at pharmaceutical enterprises in the industry.

In the journal «ScienceRise: Pharmaceutical Science» publishes research designed and implemented taking into account the Quality by design concept with widespread use of computational methods.

Innovations in pharmaceutical science - for practical use.

The journal is intended for scientists, pharmacists, doctors, educators, and healthcare professionals.


Section Policies

Pharmaceutical Science

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Peer Review Process

The editorial board practices double-blind peer review. This process involves the following:

  1. First, the editors consider all manuscripts to assess their compliance with the journal subject matter and requirements.
  2. Following the decision of the editors, the manuscripts submitted are sent to at least two external experts in the corresponding field. The manuscript passes double-blind peer review, neither the authors nor the reviewers know each other.
  3. Reviewers' comments are transmitted to the authors, together with possible recommendations for the manuscript revision. The editor informs the authors, whether the manuscript is adopted without revision or authors are given the opportunity to review the manuscript and submit it again, or the manuscript is rejected.


Publication Frequency

Frequency of journal "ScienceRise: Pharmaceutical Science" is bimonthly.


Open Access Policy

The journal "ScienceRise: Pharmaceutical Science" is practicing a policy of immediate open access to published content, supporting the principles of the free flow of scientific information and global knowledge sharing for the common social progress.



This journal uses LOCKSS system for distributed archiving published content in multiple libraries and information centers. Library - project LOCKSS ensure long-term storage of comprehensive log files and automatically restoring damaged information. More details...


Ethics publications and unfair practices in connection with publications

Principles of professional ethics in the work of the editor and publisher

The editor of a peer-reviewed journal is responsible for deciding which of the articles submitted to the journal should be published. The validation of the work in question and its importance to researchers and readers must always drive such decisions.

  • An editor should make decisions on which articles to publish based on representational faithfulness and scholarly importance of the proposed work.
  • An editor should be alert to intellectual property issues and must not to publish information if there are reasons to think that it is plagiarism. ·
  • An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, social set-up or political philosophy of the authors.
  • Unpublished materials disclosed in a submitted manuscript must not be used in an editor's own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
  • An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Every reported act of unethical publishing behavior must be looked into, even if it is discovered years after publication. 


Publishers should provide reasonable practical support to editors and define the relationship between publishers, editor and other parties in a contract.

  • Publishers should protect intellectual property and copyright.
  • Publishers should foster editorial independence.
  • Publishers should work with journal editors to set journal policies appropriately and aim to meet those policies, particularly with respect to editorial independence, research ethics, authorship, transparency and integrity (for example, conflicts of interest research funding, reporting standards), peer review and the role of the editorial team beyond that of the journal editor, appeals and complaints.
  • Publishers should communicate and periodically review journal policies (for example, to authors, readers, peer reviewers).
  • Publishers should assist the parties (for example, institutions, grant funders, governing bodies) responsible for the investigation of suspected research and publication misconduct and, where possible, facilitate in the resolution of these cases.
  • Publishers are responsible for publishing corrections, clarifications and retractions.


Ethical principles in the reviewer work

Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. That is why actions of a reviewer should be unbiased.

  • Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorized by the editor.
  • Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.
  • Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer's own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
  • Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.


Principles that should guide the author of scientific publications

Authors realize that they are responsible for novelty and faithfulness of research results.

  • Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
  • An author should ensure that they have written entirely original works, and if the author has used the work and/or words of others, then this has been appropriately cited or quoted. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.
  • Proper acknowledgment of the work of others must always be given. Author should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.
  • An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. In general, an author should not submit for consideration in another journal a previously published paper.
  • All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
  • When an author discovers a significant error or inaccuracy in their own published work, it is the author's obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learns from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.


The process for handling cases requiring corrections, retractions, and editorial expressions of concern

Corrections, retractions, republications and version control

«ScienceRise: Pharmaceutical Science» journal should publish a correction notice as soon as possible detailing changes from and citing the original publication; the correction should be on an electronic or numbered print page that is included in an electronic or a print Table of Contents to ensure proper indexing.

Scientific misconduct, expressions of concern, and retraction

Scientific misconduct in research publications includes but is not necessarily limited to data fabrication; data falsification including deceptive manipulation of images; purposeful failure to disclose conflicts of interest; and plagiarism. While each of these practices is problematic, they are not equivalent. Each situation requires individual assessment by relevant stakeholders. When scientific misconduct is alleged, or concerns are otherwise raised about the conduct or integrity of work described in submitted or published papers, the editor should initiate appropriate procedures detailed by and adapted from the Committee on Publication Ethics (COPE), consider informing the institutions and funders, and may choose to publish an expression of concern pending the outcomes of those procedures. If the procedures involve an investigation at the authors’ institution, the editor should seek to discover the outcome of that investigation, notify readers of the outcome if appropriate, and if the investigation proves scientific misconduct, publish a retraction of the article. There may be circumstances in which no misconduct is proven, but an exchange of letters to the editor could be published to highlight matters of debate to readers.




National University of Pharmacy Kharkiv



Each author is expected to have made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; or have drafted the work or substantively revised it

AND to have approved the submitted version;

AND to have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved.

Submission to a «ScienceRise: Pharmaceutical Science» is taken by the journal to mean that all the listed authors have agreed all of the contents, including the author list and author contribution statements. The corresponding author is responsible for having ensured that this agreement has been reached that all authors have agreed to be so listed, and have approved the manuscript submission to the journal, and for managing all communication between the journal and all co-authors, before and after publication. The corresponding author is also responsible for submitting a competing interests' statement.

After acceptance, the corresponding author is responsible for the accuracy of all content in the proof, including the names of co-authors, addresses and affiliations.

After publication, the corresponding author is the point of contact for queries about the published paper. It is their responsibility to inform all co-authors of any matters arising in relation to the published paper and to ensure such matters are dealt with promptly. Authors of published material have a responsibility to inform the journal immediately if they become aware of any aspects that requires correction.

Any changes to the author list after submission, such as a change in the order of the authors or the deletion or addition of authors, must be approved by every author. Journal «ScienceRise: Pharmaceutical Science» editors are not in a position to investigate or adjudicate authorship disputes before or after publication. Such disagreements, if they cannot be resolved amongst authors, should be directed to the relevant institutional authority.

When submitting the manuscript, the correspondent author must provide the necessary documents.


Plagiarism and duplicate publication

Plagiarism is unacknowledged copying or an attempt to misattribute original authorship, whether of ideas, text or results. Plagiarism can be said to have clearly occurred when large chunks of text have been cut-and-pasted without appropriate and unambiguous attribution. Such manuscripts would not be considered for publication in journal «ScienceRise: Pharmaceutical Science». "Text recycling" or reuse of parts of text from an author's previous research publication is a form of self-plagiarism.

Duplicate publication occurs when an author reuses substantial parts of his or her own published work without providing the appropriate references. This can range from publishing an identical paper in multiple journals, to only adding a small amount of new data to a previously published paper.

Journal «ScienceRise: Pharmaceutical Science» editors assess all such cases on their individual merits. When plagiarism becomes evident post-publication, we may correct or retract the original publication depending on the degree of plagiarism, context within the published article and its impact on the overall integrity of the published study.

In case of detection of copyright infringement (plagiarism) after publication, the article is not deleted from the journal’s archive (on the website) and is marked as “PLAGIARISM” in accordance with international protocols of anti-plagiarism policy. This article marked as "PLAGIARISM" appears in all resources in which the journal is indexed. The editorial office may impose penalties within the framework of the material and moral damage caused to the Licensee in accordance with clause 6.4 of License agreement.

Material submitted to a «ScienceRise: Pharmaceutical Science» journal must be original and not published or submitted for publication elsewhere. This rule applies to material submitted elsewhere while the «ScienceRise: Pharmaceutical Science» journal contribution is under consideration.

All manuscripts submitted for consideration to the journal “ScienceRise: Pharmaceutical Science” are checked for uniqueness by specialized programs. A manuscript can be accepted for consideration only if it is unique at least 80%.

Also, in addition, the uniqueness of the manuscript is evaluated at the stage of double-blind peer review (as one of the criteria that is evaluated by reviewers).

If the manuscript was also submitted for consideration in another journal, the authors are required to report this when submitting the manuscript to the journal “ScienceRise: Pharmaceutical Science”.


Competing interests

In the interests of transparency and to help readers form their own judgements of potential bias, «ScienceRise: Pharmaceutical Science» journals' require authors to declare any competing financial and/or non-financial interests in relation to the work described.

Definition. For the purposes of this policy, competing interests are defined as financial and non-financial interests that could directly undermine, or be perceived to undermine the objectivity, integrity and value of a publication, through a potential influence on the judgements and actions of authors with regard to objective data presentation, analysis and interpretation.


Financial conflicts of interest include any of the following:

Funding: Research support (including salaries, equipment, supplies, and other expenses) by organizations that may gain or lose financially through this publication. A specific role for the funder in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript, should be disclosed.

Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through this publication.

Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication; consultation fees or other forms of remuneration (including reimbursements for attending symposia) from organizations that may gain or lose financially; patents or patent applications (awarded or pending) filed by the authors or their institutions whose value may be affected by publication. For patents and patent applications, disclosure of the following information is requested: patent applicant (whether author or institution), name of inventor(s), application number, status of application, specific aspect of manuscript covered in patent application.


Non-financial competing interests:

Non-financial competing interests can take different forms, including personal or professional relations with organizations and individuals. We would encourage authors and referees to declare any unpaid roles or relationships that might have a bearing on the publication process. Examples of non-financial competing interests include (but are not limited to):

  1. Unpaid membership in a government or non-governmental organization
  2. Unpaid membership in an advocacy or lobbying organization
  3. Unpaid advisory position in a commercial organization
  4. Writing or consulting for an educational company
  5. Acting as an expert witness


We recognize that some authors may be bound by confidentiality agreements. In such cases, in place of itemized disclosures, we require authors to state: "The authors declare that they are bound by confidentiality agreements that prevent them from disclosing their competing interests in this work."

We do not require authors to state the monetary value of their financial interests.


Bioethics policy

Studies involving animals and humans 

For research manuscripts reporting experiments on living vertebrates and / or higher invertebrates, the correspondent author must confirm that all experiments were performed in accordance with the relevant guidelines and rules. The manuscript should include a statement indicating the institutional and / or licensing committee approving the experiments, including any relevant details. Gender and other characteristics of animals that may affect results should be described. Details of housing and livestock should be included if they can affect experimental results. All animal experiments must comply with ARRIVE guidelines and be conducted in accordance with the Great Britain Animal (Scientific Procedures) Act 1986 and related guidelines or EU Directive 2010/63/EU on the protection of animals used for scientific purposes [http://ec.europa.eu/ environment / chemicals / lab_animals / legislation_en.htm].

For a study in which people are participants, authors must identify a committee approving the study, ensure that the work has been carried out in accordance with the Code of Ethics of the World Medical Association (Helsinki Declaration) and include in your manuscript a statement confirming that informed consent was obtained from all participants (recommendations for obtaining informed consent).

You can also read the Helsinki Declaration in Russian on the website of the Association of Clinical Research Organizations


Clinical trial registration

Prospective clinical trials should be registered prior to the registration of patients on the website or in a similar public store (trials in which the main purpose is to determine pharmacokinetics are excluded.)


Human biological samples

To describe human biological samples, we recommend that you refer to the BRISQ reporting guidelines (reporting on biological samples to improve the quality of the study) and ensure that at least level 1 characteristics are provided (link).


Publication of images of participants in human subject research

When publishing identifiable images of study participants, authors should include a statement in the published article confirming that they have received informed consent to publish the images. All reasonable measures should be taken to protect the anonymity of the patient. Black stripes above the eyes are not an acceptable means of anonymization. In some cases, we may insist on obtaining evidence of the informed consent of the authors. Images without appropriate consent will be removed from the publication.


Studies involving human embryos, gametes, and stem cells

Manuscripts reporting experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, as well as the clinical use of stem cells, should include confirmation that all experiments have been performed in accordance with relevant guidelines and the rules.

The manuscript should include an ethical statement that identifies the institutional and / or licensing committees that approve the experiments and describe any relevant details. A statement of ethics should also confirm that informed consent has been obtained from all recipients and / or donors of cells or tissues, where necessary, and describe the conditions of donation of research materials, such as human embryos or gametes. The editors may request copies of approved and edited consent documents.


Experiments involving plants or microorganisms

Experiments with plants or microorganisms taken from outside the country of the authors should have been carried out with special permission.


Botanical identity. For each cultivated medicinal plant, its botanical identity must be established and documented - scientific name (variety, species, subspecies / variety, author and family). The common name (if any) must also be indicated in the local and English languages. If necessary, other relevant information should also be indicated, including the name of the cultivar, its ecotype, chemotype and phenotype.

For cultivated plant varieties available for sale, you must specify its name, as well as the supplier. In the case of collection, breeding, distribution and cultivation of landrace in a particular region, the line should be described with its local name, indicating the sources of origin of the seed, plant or sprout material.

Selection of medicinal plants. Where appropriate, the species or botanical species that are selected for cultivation should correspond to those indicated in the national pharmacopoeia or recommended by other authoritative national documents of the country of the final consumer. In the absence of such national documents, the selection of species or botanical varieties should be based on the pharmacopoeia or other authoritative documents of other countries. In the case when medicinal plants are considered for the first time, samples or botanical varieties selected for cultivation should be defined and documented as raw materials used or described in traditional medicine of the country of origin.


Experimental data

Analytical data should be statistically processed using appropriate programs.

When establishing the structure of substances, the authors must provide sufficient experimental information, in particular, the available 1H and 13C NMR spectra, and X-ray crystalline structural determinations are necessary for metal complexes.

The author is responsible for presenting the correct chemical nomenclature and terminology.

An accurate description of each data set should be provided, which is shown and should include the number of biological repeats, the number of experiments performed, and a description and use of appropriate statistical methods. To verify the significance of differences in results, appropriate statistical methods should be used. The term “significant” should not be used unless a statistical analysis has been performed and the probability value used to determine significance (usually p-value) should be indicated. Manuscripts submitted without evidence of reproducibility will be rejected without formal review.


Applications and additional materials 

Authors who wish to publish electronic supplementary materials to their article (Excel files, images, audio and video files) can send these files along with the manuscript.


Package of documents to article

License agreement. The license agreement is necessarily signed by all authors. Scan of the license agreement must be sent by e-mail c7508990@gmail.com

Article submission form.

Conflict of interest form.


Terms of Payment

– 50.00 Euro (publication of an article of 10 pages, designed according to the requirements for articles);

– 90.00 Euro (publication of an article of 10 pages, designed according to the requirements for articles + hard copy of the journal);

– the cost of one additional page, designed according to the requirements of the journal, is 5.00 Euro.


Rules for submitting an article's manuscript

1. Read the editorial and publishing policies

Peer Review Process
Open Access Policy
Ethics publications and unfair practices in connection with publications
Plagiarism and duplicate publication
Competing interests
Bioethics policy

2. Get acquainted with the conditions of publication:

Publication Frequency
Terms of Payment 

If you have any questions regarding the conditions of publication in the journal ScienceRise: PharmaceuticalScience, you can contact the journal manager in a way convenient for you

3. Determine the type of article and execute the article in accordance with the requirements

4. Submit to the editorial 

5. You can send these documents in one of the following ways:

- By email. You can send the above documents by e-mail (sr7508990@gmail.com). In this case, the text of the letter should be as follows:

Dear Editors! 

Please find enclosed for your review an original research article, «____________» by ________________________ All authors have read and approved this version of the article. No part of this paper was published or submitted elsewhere. No conflict of interest exits in the submission of this manuscript. We appreciate your consideration of our manuscript for possible publication in journal «ScienceRise: Pharmaceutical Science», and we look forward to receiving comments from the reviewers

On behalf of all authors of this manuscript,


- Submit an article on-line using the OJS platform (Open Journal System). When submitting an article in this way, the manuscript of the article and the necessary documents are loaded into the appropriate fields (link).

6. Successfully go through the stages of editing and double-blind peer review

7. Pay for publication

8. Get the finished article in electronic form (archive

9. Receive a printed copy of the journal (a printed copy of the journal is provided only if it was ordered and paid by the authors of the article).